Rob Sambursky, MD
President and Chief Executive Officer
Rob Sambursky, MD has 20 years of industry and clinical medical experience. He is one of the original founders of RPS Diagnostics, and currently leads Lumos Diagnostics as its President and Chief Executive Officer. He has served as the acting Chief Medical Officer for either RPS Diagnostics or Lumos Diagnostics since 2008. In addition, Dr. Sambursky is a member of the Lumos Diagnostics Board of Directors, PPK Solutions Board of Directors, and serves as the Executive Chairman for Visus Therapeutics, Inc. Dr. Sambursky has a strong scientific and clinical background in medical sciences, ophthalmology and infectious disease. He has authored numerous patents and scientific papers, conceived a novel point-of-care (POC) diagnostic test platform, served as the clinical and regulatory interface that led to multiple POC diagnostic tests obtaining international regulatory clearances as well as U.S. FDA 510(k) clearances with CLIA waiver designations, and successfully commercialized multiple diagnostic tests in the U.S. and abroad.
Dr. Sambursky is a practicing, board-certified ophthalmologist with fellowship training in refractive surgery and corneal external and infectious disease. He earned a BA in Biology from Brown University, an MA in Medical Sciences with concentrations in biochemistry and microbiology from Boston University and an MD from Boston University School of Medicine. Dr. Sambursky completed his medical internship at Harvard’s Mount Auburn Hospital and both his ophthalmology residency and cornea fellowship at Wills Eye Hospital in Philadelphia.
Sacha Dopheide, PhD
Chief Technology Officer
Sacha Dopheide, PhD has more than 15 years of experience in the in vitro diagnostic device industry, ranging from point-of-care devices to laboratory analyzers. She currently serves as the company’s Chief Technology Officer and has held an executive leadership role within Lumos Diagnostics since its acquisition of Kestrel Bioscience in 2017. Dr. Dopheide has experience managing the full range of product development for both immunoassays and their accompanying electronic readers from proof of concept through development, verification and external validation trials. Dr. Dopheide has taken a leading role in identification and due diligence of M&A targets and integration activities. She also leads the Lumos Diagnostic service business unit’s business development activities, including directly conducting global market research, establishing partnerships and generating strategic product roadmaps for new tests.
Dr. Dopheide holds a BSc with First Class Honours in Biochemistry and Molecular Biology from Monash University. She received her PhD in Medicine in 2000, for which she was awarded the Victoria Fellowship for Excellence in Medical Research.
Chief Commercial Officer
Eric Perreault has more than 25 years of medical sales and marketing leadership experience. He currently serves as the company’s Chief Commercial Officer and is responsible for the development and execution of a commercialization strategy for Lumos Diagnostics, to drive revenue growth and revenue mix across the organization, building a partner and customer network, and for creating a commercial infrastructure and organization to drive market adoption of Lumos branded products.
Prior to joining Lumos Diagnostics, Mr. Perreault most recently served as the Vice President of Global Sales for Singulex, the Vice President of Global Sales and Marketing for Astute Medical, Inc. and an Area Sales Director for Biosite, Inc. Mr. Perreault has experience building and operating world-class sales organizations, strategically launching biomarker tests both internationally and in the United States, managing customer support organizations, determining market readiness during the course of product development and for creating brand identities.
Mr. Perreault graduated with a BA in Communications from Rhode Island College.
Jeffrey Bishop, PhD
Senior Vice President Research & Development
Jeffrey Bishop, PhD has more than 20 years of diagnostic industry experience. He currently serves as the company’s Senior Vice President of Research and Development. Prior to joining Lumos Diagnostics, Dr. Bishop was the Chief Scientific Officer, Senior Vice President of Diagnostic Operations and a member of the executive team at Singulex. Additionally, he held a variety of leadership positions within the research and development organization at Alere, Inc. (formerly Biosite, Inc.), including recent roles as Vice President, Research and Development for specific platforms and disease areas.
Dr. Bishop is a technical leader responsible for the successful development of more than 30 commercialized diagnostic assay products, including both instruments and assays for point-of-care, laboratory, life science and in vitro diagnostic applications. He has extensive experience with budgeting and strategic planning, clinical research and biomarker discovery, assay and system development, clinical, medical, and regulatory affairs, microfluidics, design control, and project management. Dr. Bishop has developed point-of-care assays in the areas of cardiovascular disease, infectious disease, women’s health and toxicology.
Dr. Bishop received both an MS and a PhD in Bioengineering from the University of California, San Diego and holds a BS in Chemical Engineering from Brigham Young University. He also holds an RAC certification in Regulatory Affairs.
Senior Vice President of Finance
Aaron Erlandson has more than 20 years of experience in financial leadership positions as well as a true passion for healthcare. He currently serves as the company’s Senior Vice President of Finance with responsibility for the company’s financial and accounting activities, including long-term business planning, forecasting, compliance, and audit functions. His diagnostics industry experience, with key roles in manufacturing, sales, corporate planning and analysis, has provided a deep understanding of the global value chain. Mr. Erlandson’s most recent accomplishments include global expansion projects across North America and Asia as well as developing and executing strategic investments valued over $600 million.
Mr. Erlandson earned dual undergraduate degrees in Corporate Finance and Psychology (Industrial/Organizational) from The University of Minnesota; as well as an MBA, with an emphasis in Corporate Entrepreneurship, from Babson College. He brings a unique perspective to financial and operational issues and leverages the role of finance as a change agent in organizations.
Vice President of Product & Business Development
Jeff Bauer has been working in the diagnostics industry for over 35 years. He currently serves as the company’s Vice President of Product and Business Development. Mr. Bauer founded Kestrel BioSciences, a diagnostics R&D and manufacturing service business, with operations in Bangkok, Thailand and Carlsbad, California. In 2017, Kestrel BioSciences was acquired by Planet Innovation Pty Ltd and re-branded Lumos Diagnostics. Prior to the formation of Kestrel BioSciences, Mr. Bauer co-founded Diagnostic Consulting Network (DCN) where he was the Executive Vice President and Chief Scientific Officer.
Mr. Bauer has extensive product development and manufacturing experience in both human and animal health. He has expertise in developing immunoassays, such as ELISA, enzyme immunoassays, lateral flow, and point-of-care assays. He has ushered several products through FDA 510(k) clearance and international product registrations.
Mr. Bauer is a graduate of the U.S. Army Medical School in San Antonio, TX and is a Certified Medical Technologist with a specialty in Medical Microbiology.
Senior Director of Operations
Kurt Phinney has 15 years of experience leading biomedical project management and manufacturing and serves as the company’s Senior Director of Operations. Mr. Phinney’s background includes development of biochemical assays (lateral flow, ELISA, western blot, and cell-based) with the State Laboratory Institute of Massachusetts, Immunetics and Floria Biosystems. His ongoing pursuit of novel biotechnology has resulted in multiple patents and FDA clearances. Mr. Phinney also provided consultation to biotechnology, information technology and pharmaceutical firms in the U.S. and overseas. Prior to this, he served as a Health Service Corpsman with the United States Coast Guard.
Mr. Phinney received a BS in Biology from the State University of New York at Albany.
Director of Quality and Regulatory Affairs
Huan Tran has 18 years of experience in both quality and regulatory affairs within the medical device and in vitro diagnostics industry. Mr. Tran currently serves as the company’s Director of Quality and Regulatory Affairs. He is a seasoned quality compliance leader with extensive experience in healthcare and medical device technology, data privacy, quality engineering and regulatory affairs, both in manufacturing and designing of immunoassays. Mr. Tran has specific expertise in FDA QSR, ISO 13485 certification, Canadian (CMDCAS) certification audits and HIPAA certification audits. Current responsibilities include overseeing all policies, procedures and products to ensure continued compliance with quality, regulatory and privacy requirements. Mr. Tran has proven success in achieving both U.S. and international regulatory clearances.
Mr. Tran earned a BS in Biochemistry from the University of California, San Diego and is a certified Lead Quality Management System Auditor (CLQA), Certified Quality Engineer (ASQ) and Certified HIPAA Professional (CHP).
Director of Medical Affairs
Annie Bell has more than 15 years of professional experience in the medical device and in vitro diagnostic industry including direct patient management, medical education and clinical study management. Currently serving as the Director of Medical Affairs for Lumos Diagnostics, Ms. Bell is a strategic leader with a passion for improving patient lives through early detection of disease. She has expertise in the initiation and oversight of clinical trials including FDA registration trials.
Ms. Bell holds a BS in Nursing from Pennsylvania State University, an MS in Nursing from Rush University Chicago, IL, and is a graduate of the Global Clinical Trials Clinical Research Program, Harvard Medical School, Boston MA. In addition, Ms. Bell is a Board-certified Neonatal Nurse Practitioner.